The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...

percentage of these individuals will be prescribed Leqembi or another monoclonal antibody like it that targets beta amyloid plaque build-up in the brain. Plaque accretion is hypothesized to be a c ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

maintenance regimen of Leqembi ® (lecanemab-irmb) for early Alzheimer disease. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H).

In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the ...